For the quarter ending 2025-09-30, GYRE has $159,384K in assets. $21,969K in debts. $40,402K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Inventories, net | - | 8,861 | ||
| Cash and cash equivalents | 40,402 | 36,491 | ||
| Short-term bank deposits | 19,647 | 17,874 | ||
| Notes receivable | 693 | 499 | ||
| Accounts receivable, net | 25,877 | 24,629 | ||
| Other receivables from gni-Related Party | 230 | 230 | ||
| Inventories | 8,854 | - | ||
| Receivable from gcbp-GCBiopharma Corp | 0 | 0 | ||
| Prepaid assets and other current assets | 2,873 | 2,701 | ||
| Total current assets | 98,576 | 91,285 | ||
| Property and equipment, gross | 30,542 | - | ||
| Less accumulated depreciation | 6,934 | - | ||
| Property and equipment, net | 23,608 | 23,401 | ||
| Gross carrying amount | 5,687 | - | ||
| Accumulated amortization | 840 | - | ||
| Intangible assets, net | 4,847 | 4,962 | ||
| Deferred tax assets | 6,714 | 6,134 | ||
| Long-term certificates of deposit | 20,317 | 21,528 | ||
| Other assets, noncurrent | 5,322 | 5,336 | ||
| Total assets | 159,384 | 152,646 | ||
| Accounts payable | 556 | 71 | ||
| Contract liabilities | 58 | 0 | ||
| Due to related parties | 228 | 219 | ||
| Accrued expenses and other current liabilities | 11,799 | 14,924 | ||
| Income tax payable | 2,646 | 1,084 | ||
| Operating lease liabilities, current | 626 | 622 | ||
| Cvr derivative liability | 0 | 0 | ||
| Total current liabilities | 15,913 | 16,920 | ||
| Operating lease liabilities, noncurrent | 539 | 771 | ||
| Deferred government grants | 866 | 884 | ||
| Warrant liability, noncurrent | 3,224 | 3,201 | ||
| Other noncurrent liabilities | 1,427 | 1,427 | ||
| Total liabilities | 21,969 | 23,203 | ||
| Common stock, 0.001 par value, 400,000,000 shares authorized 90,890,381 shares and 86,307,544 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 91 | 91 | ||
| Additional paid-in capital | 167,134 | 161,437 | ||
| Statutory reserve | 3,098 | 3,098 | ||
| Accumulated deficit | -66,703 | -70,313 | ||
| Accumulated other comprehensive loss | -1,700 | -2,287 | ||
| Total gyre stockholders' equity | 101,920 | 92,026 | ||
| Noncontrolling interest | 35,495 | 37,417 | ||
| Total equity | 137,415 | 129,443 | ||
| Total liabilities and stockholders' equity | 159,384 | 152,646 | ||
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)